149 related articles for article (PubMed ID: 15140857)
1. Pharmacokinetics of valaciclovir.
MacDougall C; Guglielmo BJ
J Antimicrob Chemother; 2004 Jun; 53(6):899-901. PubMed ID: 15140857
[TBL] [Abstract][Full Text] [Related]
2. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
Perry CM; Faulds D
Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
Simon MW; Fish DN; Deeter RG
Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
Steingrimsdottir H; Gruber A; Palm C; Grimfors G; Kalin M; Eksborg S
Antimicrob Agents Chemother; 2000 Jan; 44(1):207-9. PubMed ID: 10602752
[TBL] [Abstract][Full Text] [Related]
5. [Peptide transporter family].
Terada T; Inui K
Tanpakushitsu Kakusan Koso; 2001 Apr; 46(5):621-8. PubMed ID: 11296359
[No Abstract] [Full Text] [Related]
6. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat.
Burnette TC; de Miranda P
Drug Metab Dispos; 1994; 22(1):60-4. PubMed ID: 8149891
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
Anand BS; Katragadda S; Mitra AK
J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
[TBL] [Abstract][Full Text] [Related]
8. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.
Helldén A; Lycke J; Vander T; Svensson JO; Odar-Cederlöf I; Ståhle L
J Antimicrob Chemother; 2006 May; 57(5):945-9. PubMed ID: 16540518
[TBL] [Abstract][Full Text] [Related]
9. Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2.
de Vrueh RL; Smith PL; Lee CP
J Pharmacol Exp Ther; 1998 Sep; 286(3):1166-70. PubMed ID: 9732374
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects.
Gimenez F; Foeillet E; Bourdon O; Weller S; Garret C; Bidault R; Singlas E
Clin Pharmacokinet; 2004; 43(10):685-92. PubMed ID: 15244498
[TBL] [Abstract][Full Text] [Related]
11. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.
de Miranda P; Burnette TC
Drug Metab Dispos; 1994; 22(1):55-9. PubMed ID: 8149890
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of new antiherpetic agents.
Rolan P
Clin Pharmacokinet; 1995 Nov; 29(5):333-40. PubMed ID: 8582118
[TBL] [Abstract][Full Text] [Related]
13. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.
Höglund M; Ljungman P; Weller S
J Antimicrob Chemother; 2001 Jun; 47(6):855-61. PubMed ID: 11389118
[TBL] [Abstract][Full Text] [Related]
14. [Risk of CNS adverse effects of aciclovir and valaciclovir. Watch the renal function in treatment of herpes simplex and herpes zoster].
Helldén A; Bergman U; Dwyer R; Medin C; Molanaei H; Ståhle L; Thylén P; Odar-Cederlöf I
Lakartidningen; 2007 Jun 13-26; 104(24-25):1916-20. PubMed ID: 17674672
[No Abstract] [Full Text] [Related]
15. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters.
Landowski CP; Sun D; Foster DR; Menon SS; Barnett JL; Welage LS; Ramachandran C; Amidon GL
J Pharmacol Exp Ther; 2003 Aug; 306(2):778-86. PubMed ID: 12750437
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
[TBL] [Abstract][Full Text] [Related]
17. Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin.
Soul-Lawton JH; Weatherley BC; Posner J; Layton G; Peck RW
Br J Clin Pharmacol; 1998 Jan; 45(1):87-9. PubMed ID: 9489600
[TBL] [Abstract][Full Text] [Related]
18. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
Soul-Lawton J; Seaber E; On N; Wootton R; Rolan P; Posner J
Antimicrob Agents Chemother; 1995 Dec; 39(12):2759-64. PubMed ID: 8593015
[TBL] [Abstract][Full Text] [Related]
19. Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid.
de Bony F; Bidault R; Peck R; Posner J
J Antimicrob Chemother; 1996 Feb; 37(2):383-7. PubMed ID: 8707752
[TBL] [Abstract][Full Text] [Related]
20. Valaciclovir (BW256U87): the L-valyl ester of acyclovir.
Jacobson MA
J Med Virol; 1993; Suppl 1():150-3. PubMed ID: 8245883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
